ID   I-45-BTZ-R
AC   CVCL_M201
DR   Wikidata; Q54897074
RX   PubMed=20482802;
CC   Selected for resistance to: ChEBI; CHEBI_52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (from parent cell line).
DI   NCIt; C45663; Pleural sarcomatoid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M200 ! I-45
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 10
//
RX   PubMed=20482802; DOI=10.1186/1476-4598-9-110; PMCID=PMC2882347;
RA   Zhang L.-D., Littlejohn J.E., Cui Y., Cao X.-B., Peddaboina C.,
RA   Smythe W.R.;
RT   "Characterization of bortezomib-adapted I-45 mesothelioma cells.";
RL   Mol. Cancer 9:110.1-110.9(2010).
//